Butterfly Network Secures FDA Approval, Stock Surges 90%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 9 hours ago
0mins
Should l Buy BFLY?
Source: Yahoo Finance
- FDA Approval for New Tool: On March 30, Butterfly Network announced it secured FDA approval for its AI-powered handheld ultrasound tool that estimates gestation age in under two minutes, significantly enhancing clinical decision-making efficiency, especially in emergencies or rural settings.
- Massive Market Potential: According to Fortune Business Insights, the global handheld ultrasound market is projected to grow from $397.29 million in 2025 to $1.13 billion by 2034, with Butterfly Network aiming to capture a share of this rapidly expanding market.
- Strong Financial Performance: In Q4 2025, Butterfly reported revenue of $31.5 million, a 41% year-over-year increase that exceeded the consensus estimate of $25.6 million, indicating robust growth potential in the medical imaging device sector.
- Healthy Cash Flow: Butterfly ended 2025 with $150.5 million in cash reserves, enhancing its financial flexibility in market competition and supporting future product development and market expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BFLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BFLY
Wall Street analysts forecast BFLY stock price to fall
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.290
Low
4.00
Averages
4.25
High
4.50
Current: 5.290
Low
4.00
Averages
4.25
High
4.50
About BFLY
Butterfly Network, Inc. is a healthcare company focused on medical imaging with its Ultrasound-on-Chip semiconductor technology and ultrasound software solutions. The Company's solution, leveraging its Ultrasound-on-Chip technology, enables the practical application of ultrasound information into the clinical workflow. Its product portfolio includes a combination of hardware and software, including Butterfly iQ3, Butterfly iQ+, Butterfly iQ+ Bladder, and Butterfly iQ+ Vet devices, software subscriptions, and professional services. It offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials as well as its ScanLab education-only app, formal education programs through its Butterfly Academy software and Butterfly Certified courses, as well as professional services for large scale deployments. Its devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, and Australia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Butterfly Network Secures FDA Approval, Stock Surges 90%
- FDA Approval for New Tool: On March 30, Butterfly Network announced it secured FDA approval for its AI-powered handheld ultrasound tool that estimates gestation age in under two minutes, significantly enhancing clinical decision-making efficiency, especially in emergencies or rural settings.
- Massive Market Potential: According to Fortune Business Insights, the global handheld ultrasound market is projected to grow from $397.29 million in 2025 to $1.13 billion by 2034, with Butterfly Network aiming to capture a share of this rapidly expanding market.
- Strong Financial Performance: In Q4 2025, Butterfly reported revenue of $31.5 million, a 41% year-over-year increase that exceeded the consensus estimate of $25.6 million, indicating robust growth potential in the medical imaging device sector.
- Healthy Cash Flow: Butterfly ended 2025 with $150.5 million in cash reserves, enhancing its financial flexibility in market competition and supporting future product development and market expansion.
See More
Butterfly Network Receives FDA Clearance for AI Gestational Age Tool
- FDA Approval: Butterfly Network's fully automated Gestational Age Tool has received FDA clearance, marking it as the first blind-sweep ultrasound AI tool aimed at enhancing the timeliness and accuracy of maternal care globally, which is expected to significantly reduce maternal and fetal mortality rates.
- Technological Innovation: The tool employs deep learning models to deliver reliable gestational age estimates in under two minutes, minimizing user variability and improving decision-making efficiency in emergency settings, particularly in resource-limited areas.
- Global Impact: Already deployed in Malawi and Uganda, the tool aims to improve access to prenatal ultrasound in countries with high maternal and neonatal mortality rates, and FDA clearance will expedite its expansion across Sub-Saharan Africa, supporting global health initiatives.
- Market Potential: With the U.S. federal rural health transformation initiatives underway, the launch of this tool comes at a crucial time, expected to provide easier access to healthcare for pregnant women in remote areas, thereby enhancing overall healthcare accessibility.
See More
Butterfly Network and GE Healthcare's AI Technology Competition
- Butterfly Financial Improvement: Butterfly Network achieved positive cash flow in Q1 2026 with revenue of $31.5 million, a 44% year-over-year increase, despite a per-share loss improving from $0.08 to $0.06, indicating initial success in its transition to a software platform that may attract more investor interest in its growth potential.
- GE Healthcare AI Strategy: GE Healthcare's Edison Digital Health Platform features over 40 AI applications, with the latest FDA-approved Photonova Spectra CT scanner enhancing imaging quality for cardiology patients by counting and measuring individual X-ray photons, showcasing its technological advancements and market competitiveness in medical imaging.
- Market Competition Dynamics: Although GE Healthcare's market cap is over 30 times that of Butterfly Network, its stock has declined more than 11% in the past year, reflecting market caution regarding its shift to AI software, while Butterfly Network's innovative CMUT technology and lower device costs demonstrate higher growth potential.
- Investment Risk Assessment: As a younger company, Butterfly Network faces risks due to lack of profitability and economic downturn threats, while GE Healthcare, with stable cash flow and a diverse product line, presents a stronger risk mitigation profile, potentially making it a safer investment choice.
See More
Medical Diagnostic Stocks Benefit from AI Surge
- Butterfly Network's Recovery: Butterfly Network has successfully transitioned from hardware sales to a software platform and AI company by utilizing capacitive micromachined ultrasonic transducer technology, achieving its first positive cash flow in Q1 2026, with stock prices rising over 9%.
- Significant Revenue Growth: The company reported Q4 revenue of $31.5 million, a 44% year-over-year increase, with software and services accounting for 43% of total revenue, indicating high-margin potential in its software business, although it still posted a loss per share that needs monitoring for profitability.
- GE HealthCare's Transition Challenges: Despite being over 30 times larger than Butterfly Network, GE HealthCare's shares have fallen over 11% in the past year as it shifts focus from medical device hardware to AI software aimed at improving image quality and hospital workflows.
- AI Application Approval: GE HealthCare's latest AI-powered application, Photonova Spectra, has received FDA clearance to enhance CT scans for cardiology patients, with projected organic revenue growth of 3% to 4% in 2026, showcasing its ongoing investment potential in AI.
See More
Benzinga Stock Whisper Index Analysis for the Week Ending March 6
- Investor Focus: Benzinga's Stock Whisper Index utilizes proprietary data and pattern recognition each week to highlight five undervalued and under-followed stocks, aiding investors in uncovering potential opportunities.
- Information Overload Challenge: Retail traders face the challenge of sifting through an abundance of methods to identify stocks worth attention, underscoring the complexity of market information.
- Market Dynamics Tracking: Benzinga Pro offers the latest market dynamics and headlines, ensuring investors can stay updated on significant events and trends that impact the market, enhancing decision-making efficiency.
- Future Report Preview: Benzinga encourages investors to look forward to next week's report, continuously tracking market movements to seize potential investment opportunities.
See More
VentriPoint Partners with LG Consulting for VMS+ Deployment
- Market Potential: The AI medical imaging market is projected to reach nearly $20 billion by 2033, growing at a CAGR of 34.7%, indicating a rapid increase in demand for AI technologies in healthcare, which positions VentriPoint favorably for market share expansion.
- Echocardiography Growth: The echocardiography market is expected to grow to $2.64 billion by 2030, driven by hospitals' dual demand for economic value and clinical accuracy, making VentriPoint's VMS+™ system well-suited to meet this market need.
- Strategic Partnership: The commercial agreement between VentriPoint and LG Consulting Solutions will support the deployment of the VMS+™ system across Northern California, with LG providing economic analysis and clinical implementation support to help hospitals evaluate the economic and clinical value of VMS+™, thereby accelerating technology adoption.
- Demonstration Platform Development: LG Consulting Solutions will purchase a VMS+™ system as a demonstration platform to support hospital engagement, clinician training, and economic value assessments, which not only enhances cardiac care pathways but also presents potential revenue-sharing opportunities for VentriPoint.
See More
Butterfly Network Secures FDA Approval, Stock Surges 90%
- FDA Approval for New Tool: On March 30, Butterfly Network announced it secured FDA approval for its AI-powered handheld ultrasound tool that estimates gestation age in under two minutes, significantly enhancing clinical decision-making efficiency, especially in emergencies or rural settings.
- Massive Market Potential: According to Fortune Business Insights, the global handheld ultrasound market is projected to grow from $397.29 million in 2025 to $1.13 billion by 2034, with Butterfly Network aiming to capture a share of this rapidly expanding market.
- Strong Financial Performance: In Q4 2025, Butterfly reported revenue of $31.5 million, a 41% year-over-year increase that exceeded the consensus estimate of $25.6 million, indicating robust growth potential in the medical imaging device sector.
- Healthy Cash Flow: Butterfly ended 2025 with $150.5 million in cash reserves, enhancing its financial flexibility in market competition and supporting future product development and market expansion.
See More
Butterfly Network Receives FDA Clearance for AI Gestational Age Tool
- FDA Approval: Butterfly Network's fully automated Gestational Age Tool has received FDA clearance, marking it as the first blind-sweep ultrasound AI tool aimed at enhancing the timeliness and accuracy of maternal care globally, which is expected to significantly reduce maternal and fetal mortality rates.
- Technological Innovation: The tool employs deep learning models to deliver reliable gestational age estimates in under two minutes, minimizing user variability and improving decision-making efficiency in emergency settings, particularly in resource-limited areas.
- Global Impact: Already deployed in Malawi and Uganda, the tool aims to improve access to prenatal ultrasound in countries with high maternal and neonatal mortality rates, and FDA clearance will expedite its expansion across Sub-Saharan Africa, supporting global health initiatives.
- Market Potential: With the U.S. federal rural health transformation initiatives underway, the launch of this tool comes at a crucial time, expected to provide easier access to healthcare for pregnant women in remote areas, thereby enhancing overall healthcare accessibility.
See More
Butterfly Network and GE Healthcare's AI Technology Competition
- Butterfly Financial Improvement: Butterfly Network achieved positive cash flow in Q1 2026 with revenue of $31.5 million, a 44% year-over-year increase, despite a per-share loss improving from $0.08 to $0.06, indicating initial success in its transition to a software platform that may attract more investor interest in its growth potential.
- GE Healthcare AI Strategy: GE Healthcare's Edison Digital Health Platform features over 40 AI applications, with the latest FDA-approved Photonova Spectra CT scanner enhancing imaging quality for cardiology patients by counting and measuring individual X-ray photons, showcasing its technological advancements and market competitiveness in medical imaging.
- Market Competition Dynamics: Although GE Healthcare's market cap is over 30 times that of Butterfly Network, its stock has declined more than 11% in the past year, reflecting market caution regarding its shift to AI software, while Butterfly Network's innovative CMUT technology and lower device costs demonstrate higher growth potential.
- Investment Risk Assessment: As a younger company, Butterfly Network faces risks due to lack of profitability and economic downturn threats, while GE Healthcare, with stable cash flow and a diverse product line, presents a stronger risk mitigation profile, potentially making it a safer investment choice.
See More
Medical Diagnostic Stocks Benefit from AI Surge
- Butterfly Network's Recovery: Butterfly Network has successfully transitioned from hardware sales to a software platform and AI company by utilizing capacitive micromachined ultrasonic transducer technology, achieving its first positive cash flow in Q1 2026, with stock prices rising over 9%.
- Significant Revenue Growth: The company reported Q4 revenue of $31.5 million, a 44% year-over-year increase, with software and services accounting for 43% of total revenue, indicating high-margin potential in its software business, although it still posted a loss per share that needs monitoring for profitability.
- GE HealthCare's Transition Challenges: Despite being over 30 times larger than Butterfly Network, GE HealthCare's shares have fallen over 11% in the past year as it shifts focus from medical device hardware to AI software aimed at improving image quality and hospital workflows.
- AI Application Approval: GE HealthCare's latest AI-powered application, Photonova Spectra, has received FDA clearance to enhance CT scans for cardiology patients, with projected organic revenue growth of 3% to 4% in 2026, showcasing its ongoing investment potential in AI.
See More
Benzinga Stock Whisper Index Analysis for the Week Ending March 6
- Investor Focus: Benzinga's Stock Whisper Index utilizes proprietary data and pattern recognition each week to highlight five undervalued and under-followed stocks, aiding investors in uncovering potential opportunities.
- Information Overload Challenge: Retail traders face the challenge of sifting through an abundance of methods to identify stocks worth attention, underscoring the complexity of market information.
- Market Dynamics Tracking: Benzinga Pro offers the latest market dynamics and headlines, ensuring investors can stay updated on significant events and trends that impact the market, enhancing decision-making efficiency.
- Future Report Preview: Benzinga encourages investors to look forward to next week's report, continuously tracking market movements to seize potential investment opportunities.
See More
VentriPoint Partners with LG Consulting for VMS+ Deployment
- Market Potential: The AI medical imaging market is projected to reach nearly $20 billion by 2033, growing at a CAGR of 34.7%, indicating a rapid increase in demand for AI technologies in healthcare, which positions VentriPoint favorably for market share expansion.
- Echocardiography Growth: The echocardiography market is expected to grow to $2.64 billion by 2030, driven by hospitals' dual demand for economic value and clinical accuracy, making VentriPoint's VMS+™ system well-suited to meet this market need.
- Strategic Partnership: The commercial agreement between VentriPoint and LG Consulting Solutions will support the deployment of the VMS+™ system across Northern California, with LG providing economic analysis and clinical implementation support to help hospitals evaluate the economic and clinical value of VMS+™, thereby accelerating technology adoption.
- Demonstration Platform Development: LG Consulting Solutions will purchase a VMS+™ system as a demonstration platform to support hospital engagement, clinician training, and economic value assessments, which not only enhances cardiac care pathways but also presents potential revenue-sharing opportunities for VentriPoint.
See More
